Literature DB >> 31922199

Acute myeloid leukemia immune escape by epigenetic CD48 silencing.

Zhiding Wang1,2, Yang Xiao2, Wei Guan2, Mengzhen Wang2, Jinghong Chen1, Linlin Zhang2, Yan Li2, Qian Xiong3, Hong Wang2,4, Maoquan Wang2,4, Yuyan Li2, Na Lv1,2, Yonghui Li2, Lixin Wang1, Li Yu1,2.   

Abstract

Acute myeloid leukemia (AML) is a malignant disorder of hemopoietic stem cells. AML can escape immunosurveillance of natural killer (NK) by gene mutation, fusions and epigenetic modification. The mechanism of AML immune evasion is not clearly understood. Here we show that CD48 high expression is a favorable prognosis factor that is down-regulated in AML patients, which can help AML evade from NK cell recognition and killing. Furthermore, we demonstrate that CD48 expression is regulated by methylation and that a hypomethylating agent can increase the CD48 expression, which increases the NK cells killing in vitro. Finally, we show that CD48 high expression can reverse the AML immune evasion and activate NK cells function in vivo. The present study suggests that a combination the hypomethylating agent and NK cell infusion could be a new strategy to cure AML.
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  AML; CD48; Methylation; NK

Mesh:

Substances:

Year:  2020        PMID: 31922199     DOI: 10.1042/CS20191170

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  4 in total

Review 1.  Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  Kah Keng Wong; Rosline Hassan; Nik Soriani Yaacob
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

Review 2.  One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia.

Authors:  Zhiding Wang; Jinghong Chen; Mengzhen Wang; Linlin Zhang; Li Yu
Journal:  Front Immunol       Date:  2021-04-01       Impact factor: 7.561

3.  A novel prognostic signature based on immune-related genes of diffuse large B-cell lymphoma.

Authors:  Zizheng Wu; Qingpei Guan; Xue Han; Xianming Liu; Lanfang Li; Lihua Qiu; Zhengzi Qian; Shiyong Zhou; Xianhuo Wang; Huilai Zhang
Journal:  Aging (Albany NY)       Date:  2021-10-05       Impact factor: 5.682

4.  Bioinformatics analysis of the clinical significance of HLA class II in breast cancer.

Authors:  Guihua Wu; Gaofang Xiao; Yuhang Yan; Chengwei Guo; Ningdong Hu; Sandi Shen
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.